Search

The article compares the outcomes of adults with type 1 diabetes using the Omnipod 5 system with either Dexcom G6 or Freestyle Libre 2 Plus sensors. The study found no significant differences in time spent in automode or in CGM metrics between the two sensor types. While there were some differences in glucose levels, the study suggests that sensor choice with Omnipod 5 does not result in clinically meaningful differences in performance or outcomes. The study highlights the need for further research to determine if one sensor system is superior in reducing time below range and glucose variability. [Extracted from the article]

This article discusses a study on the use of the Freestyle Libre system in adults with type 2 diabetes on basal-bolus insulin regimens. The study found that there was a small reduction in glycated hemoglobin (HbA1c) levels over a three-year period, with a larger reduction observed in those with higher baseline HbA1c levels. The study suggests that the use of Freestyle Libre may be beneficial for individuals with type 2 diabetes using basal-bolus insulin regimens. However, further research is needed to determine its effectiveness in other treatment regimens and non-insulin-treated type 2 diabetes. [Extracted from the article]

The article focuses on the real-world outcomes after one year of using Omnipod 5, a tubeless automated insulin delivery (AID) system for adults with type 1 diabetes in the UK. It reports significant improvements in time in range (TIR), HbA1c, and glucose variability, with no increase in time below range (TBR). It highlights that individuals with higher baseline HbA1c and lower bolus insulin use experienced the greatest improvements.